General Information
Version
1.0.0
Revision date
2014-11-25
Product name
None identified
Product Synonyms
For dexemedotmidine hydrochloride: 1H-Imidazole, 4-(1-(2,3- dimethylphenyl)ethyl)-, monohydrochloride, (S)-; 4-((S)-alpha,2,3- trimethylbenzyl)imidazole monohydrochloride
Chemical name
Mixture
CAS No.
7647-14-5
1.2.1 Relevant identified uses
Bulk formulated pharmaceutical mixture/formulated pharmaceutical product of the substance or packaged in final form for veterinary use; indicated as a sedative and analgesic for mixture and uses cats and dogs
Emergency telephone
+1 (866) 683-0660
Icons in SDS
Company Information
company name
Putney
e-mail address of the competent person responsible for the Safety Data Sheet
customersupport@putneyvet.com
GHS Information
Signal word
None required
Section 2
SECTION 2: Hazards identification
GHS Classification Classification of the substance or mixture Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information. The classification and labelling listed below is for bulk Dexmedetomidine Hydrocholoride Sterile Injectable Solution Regulation (EC) 1272/ 2008 [GHS] Not classified HAZARDS IDENTIFICATION …continued Directive 67/548/EEC Not classified or 1999/45/EC
2.2 Label elements
CLP/GHS hazard None required
Signal word
None required CLP/GHS hazard None required US Hazard overview Note Attention None required This mixture is not classified as dangerous/hazardous according to directive 1999/
Hazard statements
CLP/GHS None required
Precautionary statements
EU symbol/indication of danger None required Risk (R) Phrase(s) None required None required
2.3 Other hazards
Dexmedetomidine hydrochloride is an α2-adrenergic agonist with potent sedative properties. The most common adverse effects reported with clinical use of mixtures containing dexmedetomidine are hypotension, bradycardia, and dry mouth. Other adverse effects include transient hypertension, fever, hypoxia, and anemia, and tachycardia episodes. Symptoms of withdrawal (e.g., nausea, vomiting, and agitation) have been reported following discontinuation after 7 days of repeated administration.
2.1 Classification of the substance or mixture
Drugs in the finished state and intended for the final user are not subject to substance or mixture
